Welcome to our dedicated page for TELO GENOMICS news (Ticker: TDSGF), a resource for investors and traders seeking the latest updates and insights on TELO GENOMICS stock.
TELO GENOMICS CORP (symbol: TDSGF) is a biotech company at the forefront of telomere technology, specializing in diagnostic and prognostic applications in the field of oncology. The company is pioneering the most comprehensive telomere platform, offering liquid biopsies and related technologies to improve patient care. With a focus on measuring genomic instability, TELO's proprietary TeloView platform provides accurate and actionable information to pathologists, clinicians, researchers, and drug developers. The company's lead application, TELO-MM, aims to revolutionize the treatment of multiple myeloma, a deadly form of blood cancer.
Rhea-AI Summary
Telo Genomics Corp. receives first patient sample for MRD study in multiple myeloma patients post-treatment, aiming to develop prognostic tests using TeloView technology. The MRD global testing market is expected to reach USD 4.1 billion by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
-
Rhea-AI Summary
Telo Genomics Corp. has engaged Trusted Health Advisors to refine and accelerate its go-to-market and partnership deployment plan for biomarker services in cancer research. The engagement will be led by industry veterans and will focus on facilitating partnerships and collaborations with various organizations. The Company's clinical studies have led to the prioritization of this engagement as part of its commercialization strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) will present TeloViewSMM at the 2023 ASH meeting, marking a significant milestone as the assay becomes commercially available. TeloViewSMM is a non-invasive liquid biopsy that utilizes 3D telomere analysis to quantify genomic instability and transformation risk, offering potential benefits for patients diagnosed with Smoldering Multiple Myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
Rhea-AI Summary
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) announces the initiation of the Physician Experience Program - SMART, an observational study for cancer treating physicians in the US to gain experience ordering and utilizing the TeloViewSMM assay. The assay uses 3-dimensional telomere analysis to quantify genomic instability and transformation risk, helping in the selection of management strategies for patients diagnosed with Smoldering Multiple Myeloma. The launch aims to improve patient management and introduce the assay to a wider physician user base.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
-
News
Rhea-AI Summary
Telo Genomics Corp. has successfully completed its certification application with the College of American Pathologists (CAP) Accreditation Office, marking a crucial step towards the full commercial availability of its TeloView diagnostic tests. The company expects to complete the CAP audit within the first quarter of 2024 and anticipates that this accreditation will facilitate wider adoption of its tests in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Telo Genomics Corp. announces that the American Society of Hematology (ASH) has accepted the results of their TeloView-SMM technical repeatability validation study for presentation at their annual meeting in December. The study, led by Dr. Hans Knecht, will be presented on December 10, 2023. ASH regulations require the study results to be under embargo until presented. The ASH Annual Meeting and Exposition will take place from December 9-12, 2023, in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.48%
Tags
Rhea-AI Summary
Telo Genomics Corp. has received its Certificate of Accreditation of ISO 15189, allowing it to offer its Laboratory Developed Tests (LDT) internationally. This accreditation is a significant achievement for the company's platform of novel cancer assays. Telo Genomics will initially focus on testing for Smoldering Multiple Myeloma (SMM), a precursor to Multiple Myeloma (MM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Telo Genomics Corp. announces the launch of its TeloViewSMM diagnostic platform to clinicians in the United States. The platform combines molecular biology and AI to analyze telomeres and predict the progression of multiple cancers, starting with Smoldering Multiple Myeloma (SMM). The test is available for physicians to order under the SMART protocol.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Summary
Telo Genomics Corp. presents positive results in assessing MRD in multiple myeloma at the IMS annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Telo Genomics Corp. achieves ISO 15189 accreditation for clinical laboratories, positioning them to offer TeloView tests as LDTs for clinical use. Telo achieved over 90% compliance in the assessment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
FAQ
What is the current stock price of TELO GENOMICS (TDSGF)?
The current stock price of TELO GENOMICS (TDSGF) is $0.0901 as of October 15, 2024.
What is the market cap of TELO GENOMICS (TDSGF)?
The market cap of TELO GENOMICS (TDSGF) is approximately 8.1M.
What is TELO GENOMICS CORP's primary focus?
TELO GENOMICS CORP specializes in telomere technology, offering diagnostic and prognostic applications in the field of oncology.
What is TELO GENOMICS CORP's lead application?
TELO GENOMICS CORP's lead application, TELO-MM, is designed to provide important, actionable information for medical professionals treating multiple myeloma.
How does TELO GENOMICS CORP's TeloView platform benefit patients?
TELO GENOMICS CORP's TeloView platform offers liquid biopsies and related technologies that improve patient care by providing accurate and actionable information to pathologists, clinicians, academic researchers, and drug developers.
What sets TELO GENOMICS CORP apart in the industry?
TELO GENOMICS CORP's proprietary TeloView platform stands out for its comprehensive telomere analysis, quantifying genomic instability with high sensitivity and offering valuable insights for oncology and genetic diseases.
How does TELO GENOMICS CORP leverage Artificial Intelligence?
TELO GENOMICS CORP has developed machine learning and AI modules, such as CellSelect-Pro, to enhance sample processing, consistency, and accuracy in its diagnostic tests, ultimately improving efficiency and cost-effectiveness.
TELO GENOMICS CORP